| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| 21 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Results support potential for differentiated clinical impact for patients suffering from chronic |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications |
| 03 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 10 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 9, 2026, by and among Cue Biopharma, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each,... |
| 03 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
At the Special Meeting of Stockholders of Cue Biopharma, Inc. (the “Company”) held on June 1, 2026 (the “Special Meeting”), the Company’s stockholders approved the Cue Biopharma, Inc. 2026 Stock Incentive Plan (the “2026 Plan”), which ha... |
| 02 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 14 May 2026 |
8-K: Financial Statements and Exhibits
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering |
| 01 May 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 30, 2026 (the “Signing Date”), by and between Ascendant Health Sciences Ltd. (the “Investor”), a corporation organized and existing under the laws of the Cayman I... |
| 22 Apr 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Cue Biopharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: |
| 13 Apr 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 annual meeting of stockholders of Cue Biopharma, Inc. (the “Company”) held on April 13, 2026 (the “Annual Meeting”), the certified results of the matters voted upon at the Annual Meeting, which are more fully described in the... |
| 07 Apr 2026 |
8-K: Other Events
On April 1, 2026, Cue Biopharma, Inc. (the “Company”) received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement en... |
| 27 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases |
| 18 Feb 2026 |
8-K: Other Events
Cue Biopharma, Inc. (the “Company”) has set April 13, 2026 as the date for the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Proposals of stockholders intended to be presented at the 2026 Annual Meeting pursu... |
| 12 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 19 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to Purchase Up to 23,214,286 Shares of Common Stock |
| 24 Nov 2025 |
8-K: Regulation FD Disclosure
On November 24, 2025, Cue Biopharma, Inc. (the “Company”) made publicly available on its website an updated corporate presentation. A copy of the presentation is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. |
| 20 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M |
Loading...